When did Acadia Pharmaceuticals report Q4 2024 earnings?

Acadia Pharmaceuticals (ACAD) reported Q4 2024 earnings on February 26, 2025 after market close.

What were Acadia Pharmaceuticals's Q4 2024 revenue and EPS?

Acadia Pharmaceuticals reported revenue of $259.6M and eps of $0.17 for Q4 2024.

Did Acadia Pharmaceuticals beat estimates in Q4 2024?

Revenue missed the consensus estimate of $273.0M by $13.4M. EPS beat the consensus estimate of $0.13 by $0.04.

Where can I find Acadia Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-029253) directly on SEC EDGAR. The filing index links above go to sec.gov.

Acadia Pharmaceuticals ACAD Q4 2024 Annual earnings

Reported February 26, 2025 · After market close

Revenue$259.6MMiss by $13.4M

EPS$0.17Beat by $0.04

Revenue estimate$273.0M

EPS estimate$0.13

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$295.5M

EPS estimate$0.06

Financials

Q4 2024

Income statement

See full

Revenue$259.6M+12.4%

Gross profit$237.8M+11.6%

Operating income$153.5M—

Net income$143.7M+214%

EPS (diluted)$0.86+207%

Balance sheet

See full

Cash & equivalents$319.6M+69.4%

Total debt$52.0M-9.1%

Total equity$732.8M+69.7%

Total assets$1.2B+58.6%

Cash flow

See full

Operating cash flow$40.4M-52.7%

CapEx$453.0K+3,524%

Free cash flow$39.9M-53.2%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$3.05B-40.6%

Enterprise value$2.79B-44.4%

P/E13.5×—

P/S3.2×-3.9×

Profitability

See full

Gross margin91.5%-2.8pp

Operating margin24.1%—

Net margin23.6%+18.7pp

Returns & leverage

See full

Return on equity38.9%+30.5pp

Debt / equity0.1×-0.1×

Current ratio2.4×0.0×

Segments

By product

See full

Nuplazid$162.9M+18.6%

Daybue$96.7M+118%

By segment

See full

Reportable Segment Aggregation Before Other Operating$259.6M+42.9%

Versus estimates

Revenue

Q1 2026$268.1MMiss by $12.2M Q4 2025$284.0MMiss by $8.8M Q3 2025$278.6MMiss by $14.0M Q2 2025$264.6MBeat by $2.6M Q1 2025$244.3MBeat by $5.3M

Q4 2024$259.6MMiss by $13.4M

Diluted EPS

Q1 2026$0.02Miss by $0.02 Q4 2025$1.60Beat by $1.46 Q3 2025$0.26Beat by $0.12 Q2 2025$0.16Beat by $0.02 Q1 2025$0.11Beat by $0.01

Q4 2024$0.17Beat by $0.04

Ask the moment Acadia Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Acadia Pharmaceuticals report Q4 2024 earnings?: Acadia Pharmaceuticals (ACAD) reported Q4 2024 earnings on February 26, 2025 after market close.
What were Acadia Pharmaceuticals's Q4 2024 revenue and EPS?: Acadia Pharmaceuticals reported revenue of $259.6M and eps of $0.17 for Q4 2024.
Did Acadia Pharmaceuticals beat estimates in Q4 2024?: Revenue missed the consensus estimate of $273.0M by $13.4M. EPS beat the consensus estimate of $0.13 by $0.04.
Where can I find Acadia Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-029253) directly on SEC EDGAR. The filing index links above go to sec.gov.